{"classes":[{"categories":[{"measurements":[{"comment":"Insufficient number of samples analyzed.","groupId":"OG000","spread":"NA","value":"1.51"},{"comment":"Insufficient number of samples analyzed.","groupId":"OG001","spread":"NA","value":"1.67"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"29"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants will receive placebo matching to atezolizumab via IV infusion on Days 1 and 15 (± 3 days) of every 28-day cycle along with paclitaxel administered at a dose of 90 mg/m\\^2 via IV infusion on Days 1, 8, and 15 of every 28-day cycle until disease progression or unacceptable toxicity.","id":"OG000","title":"Placebo and Paclitaxel"},{"description":"Participants will receive atezolizumab at a dose of 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 (± 3 days) of every 28-day cycle along with paclitaxel administered at a dose of 90 mg per square meter (mg/m\\^2) via IV infusion on Days 1, 8, and 15 of every 28-day cycle until disease progression or unacceptable toxicity.","id":"OG001","title":"Atezolizumab and Paclitaxel"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK-evaluable population: first 60 participants who received any dose of Paclitaxel and who have at least one evaluable post-baseline PK sample. For all safety, PK and immunogenicity analyses, participants were grouped according to the treatment actually received, including cases in which atezolizumab was received in error.","reportingStatus":"POSTED","timeFrame":"Pre-dose (0 hours) on Day 1 of Cycle 3 (1 Cycle = 28 days)","title":"Minimum Observed Plasma Concentration (Cmin) of Paclitaxel","type":"SECONDARY","unitOfMeasure":"ng/mL"}